Compare BDL & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BDL | MDXH |
|---|---|---|
| Founded | 1959 | 2003 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Restaurants | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 84.6M | 68.7M |
| IPO Year | 1995 | 2021 |
| Metric | BDL | MDXH |
|---|---|---|
| Price | $46.29 | $0.59 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $1.80 |
| AVG Volume (30 Days) | 21.4K | ★ 200.4K |
| Earning Date | 08-12-2026 | 11-12-2026 |
| Dividend Yield | ★ 1.29% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 3.09 | N/A |
| Revenue | ★ $205,248,000.00 | N/A |
| Revenue This Year | N/A | $5.40 |
| Revenue Next Year | N/A | $12.92 |
| P/E Ratio | $15.01 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $27.55 | $0.40 |
| 52 Week High | $52.12 | $5.33 |
| Indicator | BDL | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 54.14 | 44.04 |
| Support Level | $29.36 | $0.51 |
| Resistance Level | $47.99 | $0.64 |
| Average True Range (ATR) | 1.91 | 0.04 |
| MACD | 0.16 | -0.00 |
| Stochastic Oscillator | 73.78 | 51.98 |
Flanigan'S Enterprises Inc operates as a chain of small cocktail lounges and packages liquor stores throughout South Florida. The business activity is principally conducted in two segments namely Restaurant and Package liquor store segment. Its Restaurant segment offers alcoholic beverages and full food service, and Package stores consist of retail liquor sales and related items. Its menu consists of a wide variety of options including prime rib, steaks, pasta, entree salads, burgers, a variety of sandwiches, and oversized signature desserts. The company generates maximum revenue from Restaurant segment.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.